TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.~* Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.~* Must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation.~Key Exclusion Criteria:~* No pigmented hair within any of the vitiligo areas on the face.~* Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).~* Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.~* Use of protocol-defined treatments within the indicated washout period before baseline.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
- Double-Blind Period: Vehicle cream BID (Type: PLACEBO_COMPARATOR): Participants applied matching vehicle cream BID for 24 weeks.
- Treatment-Extension Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
- Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic scalp psoriasis for at least the previous six months~* Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher of scalp surface area affected~* Must be candidates for systemic therapy, which means having scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque~* Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)~* Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)~* Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors~* Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer~* Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab~* Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Harm Reduction With Pharmacotherapy (HaRP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* being a registered client at one of the named partnering sites~* being at least 21 years of age (for legal reasons)~* agreeing to use an adequate form of birth control (if female and in childbearing years) fulfilling criteria for current alcohol dependence according to DSM-IV-TR criteria as determined by the SCID-I/P~Exclusion Criteria:~* refusal or inability to consent to participation in research~* constituting a risk to safety and security of other clients or staff~* known sensitivity or allergy to naltrexone/XR-NTX~* current treatment with naltrexone/XR-NTX~* being pregnant or nursing~* suicide attempts within the past year~* renal insufficiency/serum creatinine level \> 1.5~* current opioid dependence according to the DSM-IV-TR criteria~* liver transaminases (AST, ALT) \> 5 times the upper limit of normal (ULN)~* clinical diagnosis of decompensated liver disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Assessment-only (Type: NO_INTERVENTION): Assessment-only control condition
- HRC (Type: ACTIVE_COMPARATOR): Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
- XR-NTX+HRC (Type: EXPERIMENTAL): 3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
- Placebo+HRC (Type: PLACEBO_COMPARATOR): 3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II 5-Azacytidine Plus VPA Plus ATRA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory or relapsed: acute myelogenous leukemia (AML), and myelodysplastic syndrome (MDS) (bone marrow blasts \> or = 10%) are eligible.~* Untreated patients older than 60 years of age with AML or MDS (bone marrow blasts \> or = 10%) who refuse or are not eligible for front-line chemotherapy, are eligible.~* Performance status of \< or = 2 by the Eastern Cooperative Oncology Group (ECOG) scale.~* Signed informed consent indicating that patients are aware of the investigational nature of this study in keeping with the policies of University of Texas M D Anderson Cancer Center (UTMDACC).~* Age \> 2 years. Valproic acid has been associated with a higher rate of severe liver toxicity in children younger than 2 years.~* Patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Use of hydroxyurea for patients with rapidly proliferative disease is allowed for the first two weeks on therapy.~* Adequate liver function (bilirubin of \< 2mg/dL, SGPT \< 3 \* ULN) and renal function (creatinine \< 2mg/dL).~* Women of childbearing potential must practice contraception. Men and women must continue birth control for the duration of the trial.~* Patients with relapsed /refractory disease with inv16, t(8;21) or t(15;17) are eligible.~Exclusion Criteria:~* Nursing and pregnant females are excluded.~* Patients with active and uncontrolled infections are excluded.~* Patients already receiving valproic acid or receiving other anticonvulsants will be excluded.~* Untreated patients younger than 60 years will not be candidates for this study.~* Patients with untreated disease inv16, t(8;21) or t(15;17) will be excluded.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VPA + 5-aza + ATRA (Type: EXPERIMENTAL): Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m\^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with gestation age ≤ 32weeks~* Within 72 hours after birth~* Written informed consent obtained from parents~Exclusion Criteria:~* Genetic or metabolic diseases~* Congenital abnormalities~* Polycythemia~* Intracranial hemorrhage grade III/IV~* Unstable vital signs (such as respiration and circulation failure)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
- Normal saline (Type: PLACEBO_COMPARATOR): Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Stimulant Drugs on Social Perception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* High school degree~* English fluency~* Healthy~* Has used MDMA~Exclusion Criteria:~* Pregnant or trying to become pregnant~* Any medical or psychiatry condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will attend one session during which they will receive a placebo capsule.
- Low dose MDMA (Type: EXPERIMENTAL): Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
- High dose MDMA (Type: EXPERIMENTAL): Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
- Methamphetamine (Type: EXPERIMENTAL): Subjects will attend one session during which they will receive 20mg methamphetamine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofogliflozin GLP-1 Analogue Combination Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject aged from 20 to 75 years old with type 2 diabetes mellitus(T2DM)~* The subject with hemoglobin A1c ≧7.5% - \<10.5 %~* The subject who has been receiving a stable dose and regimen of GLP-1 analogue over 8 weeks before Screening test~Exclusion Criteria:~* The subject with type 1 diabetes mellitus~* The subject with Pregnancy or lactation~* The subject with Fasting Plasma Glucose ≧ 270 mg/dl~* The subject with history of metabolic acidosis, including diabetic ketoacidosis ,within 1 year prior to screening~* The subject with myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months~* The subject with serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women~* The subject with aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧ 2.5 times the upper limit of the reference range at the central laboratory test facility~* The subject has received treatment with another investigational product or non-approved drug 3 months before screening~* The subject with history of Tofogliflozin therapy~* The subject with estimated glomerular filtration rate of \<30 mL/min/1.73 m\^2~* The subject who frequently experiencing orthostatic hypotension~* The subject systolic blood pressure of ≧ 180 or mmHg of diastolic blood pressure of ≧ 100 mmHg~* The subject required a change in the dosing regiment for the following drugs within 4 weeks before screening : Lipid-lowering drug , Antihypertensive drug, Thyroid hormone drug , Uric acid lowering drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tofogliflozin ＋GLP-1 analogue (Type: EXPERIMENTAL): Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pramlintide in Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 13 and 17 years of age, inclusive~* Diagnosed with type 1 diabetes for \> 1 year~* Hemoglobin A1c between 7.5 and 10% inclusive~* Currently using carbohydrate to insulin ratio~* Acceptable form of birth control~Exclusion Criteria:~* Use of oral hyperglycemic agents or medications affecting blood sugar levels~* Recurrent severe hypoglycemia requiring assistance in past 6 months~* History of hypoglycemia unawareness~* History of gastroparesis requiring use of drugs that stimulate gastrointestinal motility~* Previous use of pramlintide

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 Symlin (Type: EXPERIMENTAL): Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
- 2 Usual Regimen (Type: NO_INTERVENTION): Usual bolus insulin dose at each meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be included if they have physician-diagnosed chronic urticaria and/or angioedema (CUA). CUA is defined by having urticarial wheals (hives) and/or angioedema (dermal swelling) on a daily or almost daily for more than 6 weeks. Patients with CUA also having signs of dermatographism and/or delayed-pressure urticaria will be included in the study. Subjects with history of intolerance to non-steroidal anti-inflammatory drugs will be included but warned not to take this drug class (acetaminophen will be allowed instead).~Exclusion Criteria:~* Subjects will be excluded if:~  1. They are not capable of answering the questionnaire.~ 2. Subjects with a pure physical or allergic urticarias, and/or hereditary and acquired angioedema (C1 esterase inhibitor deficiency). These subjects will be excluded as the etiology of their disease is known.~ 3. Pregnant or lactating women. All child-bearing women will be asked (verbally and on the questionnaire) if they are pregnant or lactating. If they answer yes, they will be excluded. As there is no risk or harm to the pregnant or lactating woman, a urine pregnancy test will not be used.~ 4. Subjects with any clinically significant abnormality in biochemistry testing, and/or hypercalcemia (calcium \> 10.3 mg/dl) or renal insufficiency (GFR\< 50 ml/min).~ 5. Subjects with a history of primary hyperparathyroidism, renal tubular acidosis, sarcoidosis, granulomatous disease, or malignancy.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 4000 IU (Type: EXPERIMENTAL): Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily.
- Vitamin D3 600 IU (Type: ACTIVE_COMPARATOR): Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have chronic plaque psoriasis for at least 6 months.~Exclusion Criteria:~* Participant must not be breastfeeding or nursing woman.~* Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.~* Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.~* Participant must not have any other skin conditions (excluding psoriasis).~* Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).~* Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.~* Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250mg Q4W/250mg Q8W Mirikizumab (Type: EXPERIMENTAL): Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
- 250mg Q4W/125mg Q8W Mirikizumab (Type: EXPERIMENTAL): Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
- Placebo/250mg Mirikizumab (Type: EXPERIMENTAL): Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
- 300mg Secukinumab (Type: ACTIVE_COMPARATOR): Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
- Japan GPP/EP (Type: EXPERIMENTAL): Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Bicarbonate in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age above 70 years~* Preexisting renal impairment (preoperative serum creatinine level \>120µmol/L~* New York Heart Association class III/IV or Moderate to poor left ventricular dysfunction~* Valve surgery or complex cardiac surgery~* Redo cardiac surgery~* Insulin-dependent diabetes mellitus~Exclusion Criteria:~* Age \<18 years~* Emergency cardiac surgery~* Planned off-pump cardiac surgery~* Enrolled in conflicting research study~* Known blood-borne infectious disease~* Chronic inflammatory disease on immunosuppression~* Chronic moderate to high dose corticosteroid therapy (\>10mg/d prednisone or equivalent)~* End stage renal disease (serum creatinine \>300µmol/L)~* Thiamine deficiency will be excluded on medical and dietary history.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete